Neurotrophic effects of bone morphogenetic protein-7 in a rat model of Parkinson's disease
Related Experiment Video
Updated: Aug 22, 2026

The 6-hydroxydopamine Rat Model of Parkinson's Disease
Published on: October 27, 2021
1National Institute on Drug Abuse, NIH, Neural Protection and Regeneration Section, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA.
Abstract:
Previous studies have demonstrated that pretreatment with bone morphogenetic protein-7 (BMP7) reduces ischemic neuronal injury in vivo. Moreover, exogenous application of BMP7 increases both the number of tyrosine hydroxylase (+) cells and dopamine (DA) uptake in rat mesencephalic cell cultures. The purpose of this study was to investigate the in vivo effects of BMP7 on 6-hydroxydopamine (6-OHDA) induced lesioning of midbrain DA neurons. Adult Fischer 344 rats were anesthetized and injected with BMP7 or vehicle into the left substantia nigra, followed by local administration of 9 microg of 6-OHDA into the left medial forebrain bundle. The lesioned animals that received BMP7 pretreatment, as compared to vehicle/6-OHDA controls, had a significant reduction in methamphetamine-induced rotation 1 month after the surgery. BMP7-pretreatment partially preserved KCl-induced dopamine release in the lesioned striatum and significantly increased TH immunoreactivity in the lesioned nigra and striatum. In summary, our data suggest that BMP7 has neuroprotective and/or neuroreparative effects against 6-OHDA lesioning of the nigrostriatal DA pathway in an animal model of Parkinson's disease (PD).
Related Concept Videos
Parkinson Disease ll: Pathophysiology
Parkinson's Disease: Overview
Parkinson Disease l: Introduction
Neural Regulation
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

